Current Treatment Guidelines of SARS-CoV-2 Related Multisystem Inflammatory Syndrome in Children: A Literature Review and Expert Opinion

Alireza Ghodsi1* Mehrdad Sarabi1 Abdolreza Malek2 Ali Khakshour2

1 Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2 Department of Pediatrics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Address for correspondence Abdolreza Malek, Department of Pediatrics, Faculty of Medicine, Mashhad University of Medical Sciences, Azadi Square, Mashhad, Iran (e-mail: malekar@mums.ac.ir).

J Child Sci 2021;11:e133–e140.

Abstract

Multisystem inflammatory syndrome in children (MIS-C) is a systemic disorder that seems to be associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since April 2020, there have been multiple reports about children with this new condition worldwide, including Europe, Asia, Latin America, and North America. The symptoms of this syndrome mimic the clinical manifestations of Kawasaki disease; therefore, the treatment of Kawasaki disease, as well as supportive care, was the management of choice in children with MIS-C in the early days of recognizing it. It is important to precisely ascertain the risk of COVID-19 infection and its severity in children and to acknowledge the management of this syndrome, with reliable data from cohorts, trials, and experts’ opinions. In the current review, we summarize the current management guidelines for MIS-C and present our own protocol to answer some clinical questions regarding MIS-C management during the COVID-19 pandemic.

Keywords

► COVID-19
► SARS-CoV-2
► multisystem inflammatory syndrome in children
► treatment
► guideline

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread worldwide and led to an emerging pandemic, which has affected all age groups including newborns.1,2 In the beginning, it was assumed that SARS-CoV-2 causes mild respiratory symptoms in children,1 but in late April 2020, some reports showed a new clinical syndrome in children resembling Kawasaki disease and toxic shock syndrome.3,4 Kawasaki disease is an acute medium-vessel vasculitis that causes fever, mucus inflammatory manifestation (e.g., strawberry tongue), skin rash, and lymphadenopathy.5 The etiology of Kawasaki disease remains unclear, but various theories including viral infection have been proposed.6,7 Although this new syndrome seems to mimic Kawasaki disease, there are several clinical and laboratory factors that can partly distinguish multisystem inflammatory syndrome in children (MIS-C) from Kawasaki disease.8,9

Since MIS-C is a new condition, the benefit and efficacy of various treatments are not fully evident yet.9 For children with a mild presentation, only supportive care and follow-up are recommended.10 Other cases with moderate-to-severe clinical manifestations should be admitted to the hospital to receive appropriate treatment and to be monitored closely in case a pediatric intensive care unit (PICU) admission is required.11 Various terms have been used to refer to this hyperinflammatory response in pediatrics, including pediatric multisystem inflammatory syndrome, pediatric COVID-19 associated inflammatory disorder, hyperinflammatory shock in children with COVID-19, “Kawashocky,” “Coronasacki,” and MIS-C. We will use the term MIS-C for the purposes of this review.
Several children with symptoms indicating Kawasaki disease or MIS-C, according to the criteria provided by the Center for Disease Control and Prevention (CDC), were also referred to the hospitals affiliated to Mashhad University of Medical Sciences. In the current article, we review and summarize several guidelines for MIS-C management. We also render a guideline via advice from pediatric infectious disease specialists, pediatric rheumatologists, and pediatric cardiologists on the management of MIS-C cases in our centers.

**Multisystem Inflammatory Syndrome in Children Definitions**

Three MIS-C definitions put forth by CDC, World Health Organization, and the Royal College of Pediatrics and Child Health are shown in Table 1. In all these definitions, the presence of persistent fever in addition to multisystem organ involvement without other possible diagnoses is essential. Furthermore, laboratory evidence of inflammation, SARS-CoV-2 infection confirmation, or recent exposure to a COVID-19 case is the key element in children with MIS-C. All these three guidelines have mentioned that children who present with manifestations resembling those of typical (complete) or atypical (incomplete) Kawasaki disease that also meet the criteria of MIS-C should be considered MIS-C cases. The criteria are slightly different and these definitions may even change, following the new information that is released.

**Multisystem Inflammatory Syndrome in Children versus Kawasaki Disease**

Kawasaki disease is an acute medium-vessel vasculitis that causes fever in association with signs of mucocutaneous inflammation. The diagnosis of complete Kawasaki

**Table 1** Case definition of multisystem inflammatory syndrome in children

| WHO | CDC | NHS The Royal College of Pediatrics and Child Health |
|-----|-----|-----------------------------------------------------|
| Age | <19 y | <21 y | Child |
| Fever | Fever ≥ 72 h | Subjective persistent fever more than 24 h or documented fever more than 38.0°C for more than 24 h | Persistent fever more than 38.5°C |
| Clinical presentation | Bilateral nonpurulent conjunctivitis or rash | Evidence of clinical deterioration requiring hospitalization, in addition to multiorgan dysfunction (≥2) | Single or multiple organ dysfunctions (e.g., cardiovascular, GI, renal, neurologic, or dermatologic) Supplemental oxygen requirements and low blood pressure have been reported in most pediatrics Other features, including GI symptoms (e.g., vomiting, abdominal pain, diarrhea), lymphadenopathy, sore throat, cough, rash, conjunctivitis, confusion, syncope, stomatitis, headache, respiratory symptoms, neck swelling, hand, and feet edema have been seen in some children |
| Laboratory data | Increased inflammatory factors (e.g., procalcitonin, ESR, or CRP) Abnormal coagulation test (INR, PT, PTT, and D-dimer) Evidence of coronary involvement (including a high amount of NT-proBNP /troponin or echo findings) | Hypoalbuminemia Neutrophilia Lymphocytopenia Elevated LDH, CRP, ESR, D-dimer, fibrinogen, procalcitonin, IL-6, ferritin | High ferritin and D-dimer level Abnormal fibrinogen amount Hypoalbuminemia Some cases present with AKI, high LDH, hypertransaminasemia, anemia, abnormal coagulation test, low platelets, elevated IL-6, as well as IL-10, increased creatine kinase level, high troponin, proteinuria, elevated TG |
| Evidence of COVID-19 infection (positive for any of the following factors) | Serology | + | + | NR |
| | Antigen test | + | + | NR |
| | RT-PCR | + | + | + |
| Exposure to COVID-19 patients | + | + | NR |
| Ruling out alternative plausible diagnoses, including other infectious causes (e.g., toxic shock syndrome, bacterial sepsis) | + | + | + |

Abbreviations: +, reported; AKI, acute kidney injury; APTT, activated partial thromboplastin time; COVID-19, coronavirus disease 2019; CRP, C-reactive protein; CXR, chest X-ray; echo, echocardiography; ESR, erythrocyte sedimentation rate; GI, gastrointestinal; IL, interleukin; LDH, lactic acid dehydrogenase; MIS-C, multisystem inflammatory syndrome in children; NR, not reported; NT-proBNP, N-terminal proB-type natriuretic peptide; PT, prothrombin time; PTT, partial thromboplastin time; RT-PCR, reverse transcriptase-polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TG, triglycerides.
disease, according to the American Heart Association, includes an unexplained persistent fever for 5 days in addition to four out of five clinical criteria. The presence of less than four principal clinical features would be diagnosed as incomplete Kawasaki disease (►Table 2). Some case series reported that about one-third to one-half of children with MIS-C met the full clinical criteria of Kawasaki disease. Furthermore, prominent cardiovascular involvement was seen in children with Kawasaki disease shock syndrome, which refers to a severe form of Kawasaki disease with clinical features of shock, with no evidence of infection. However, some factors help to distinguish between these two similar diseases. The common features of each disease are presented in ►Table 3.

**Clinical Findings**

Based on reports on this syndrome, persistent fever (4–6 days) and gastrointestinal symptoms (e.g., abdominal pain) are the common presentation in almost all children. The following symptoms have occurred in at least half of the patients: rash, conjunctivitis, mucous membrane involvement, neurological symptoms (e.g., headache), cardiac involvement, and respiratory symptoms (e.g., tachypnea and labored breathing). Other clinical manifestations such as sore throat, myalgia, swollen hands/feet, and lymphadenopathy have also been seen in less than 20% of MIS-C patients. The cardiac manifestations in MIS-C patients are more likely to present with cardiac dysfunction, shock, and hypotension rather than with coronary artery abnormalities. Shock was defined as tachycardia in addition to one of the following signs: decrease peripheral pulse, cold extremity, hypotension, oliguria, capillary refill time more than 3 seconds, or arterial blood lactate more than 2 mmol/L.

**Management**

MIS-C is a new phenomenon and limited studies have been conducted on this subject. Therefore, information about this syndrome, especially its management, is scarce. Due to its

| MIS-C | Kawasaki disease |
|-------|-----------------|
| Age of presentation | Older children and adolescents (usually 8–10 y) | Infants and young children |
| Gender preference | Male | Male |
| Race | Black and Hispanic | Asian |
| Fever | Present | Present |
| Gastrointestinal symptoms (particularly abdominal pain) | Very common | Less prominent |
| Lymphadenopathy | Not common | More common |
| Hypotension | Sometimes | Present |
| Rash | Present | Present |
| Desquamation | Present | Present |
| Cardiovascular complications and shock | More common | Only in children with Kawasaki disease shock syndrome |
| Inflammatory markers (especially CRP, ferritin, and D-dimer) | More elevated | Normal to elevated |
| Absolute lymphocyte and platelet counts | Reduced | Normal |
| Troponin | Elevated | Normal |
| Positive SARS-CoV-2 test and exposure history | Yes | |

Abbreviations: CRP, C-reactive protein; MIS-C, multisystem inflammatory syndrome in children; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
resemblance to Kawasaki disease, the treatment of children with MIS-C has been based on the management of Kawasaki disease as well as experts’ opinions. The coordination of various pediatric specialists in critical care units, infectious disease, rheumatology, and cardiology is necessary to manage these cases. Different treatments have been suggested by experts, but there is no evidence so far to affirm them.

The severity of the disease and its symptoms is the key element in choosing the treatment. Prescribing medications is not recommended for children who do not have severe symptoms, do not seem ill, and who do not need hospitalization. Therefore, the CDC emphasizes the importance of supportive care, including fluid resuscitation and respiratory support, along with close clinical follow-up.28,29 On the other hand, children with moderate-to-severe clinical manifestations and hemodynamic instability should be admitted to the hospital. Since the progress of MIS-C to hypotension and critical situation may be fast, these children should be managed in a center with PICU. The American Academy of Pediatrics,30 Tehran Children’s Medical Center Protocol,31 and also the guideline of the Children’s Hospital of Philadelphia32 recommend paraclinical evaluations, including laboratory and imaging assessments, to investigate potential infection and multiorgan involvement. These suggested tests in addition to the evaluation that we recommend are presented in Table 4. Renal and cardiac functions, as well as respiratory and neurological status, should carefully be monitored. It is also recommended to consider other plausible causes in the absence of a positive PCR test or any exposure to a COVID-19-infected case.9 The purpose of any treatment in MIS-C is to prevent life-threatening presentations (e.g., shock) and long-term complications such as heart failure.

Different treatment protocols have been presented, but their efficacy has been controversial. These treatment options have been established based on specific clinical manifestations, the management of similar preexisting conditions such as Kawasaki disease, and experts’ opinions. The pediatric specialists in our center arranged a guideline, considering the existing literature and worldwide evidence and their experience in managing MIS-C and other similar cases, since the beginning of the COVID-19 pandemic. These data are described in detail in Tables 5 and 6. Possible drug interactions should be considered before administering these agents.

Antipyretic therapy is an important step of supportive care. For children with fever (more than 38.5°C), paracetamol at a dosage of 10 to 15 mg/kg every 4 to 6 hours is preferred to ibuprofen, especially in dehydrated children (diarrhea or vomiting).28

Children who present with shock should immediately be resuscitated with crystalloid fluids. Most of these patients are resistant to volume expansion, so the use of vasopressor is therefore necessary. The first-line agent is epinephrine, and if the shock persists, norepinephrine is also administered. In case of severe myocardial involvement, dobutamine has also been suggested.27,33 It is also very important to monitor for volume overload. The symptoms and laboratory data (e.g., increased neutrophilia or C-reactive protein) make it hard to rule out a bacterial infection. Therefore, empirical broad-spectrum antibiotics should be initiated in patients with severe clinical presentation and should be stopped once the patient’s condition improves and an infection has been ruled out. Some of these children may need intubation or even extracorporeal membrane oxygenation.27,34,35

**Kawasaki Disease Like Features**

As mentioned above, up to 50% of MIS-C cases fulfill the diagnostic criteria of Kawasaki disease. Thus, the standard protocol for the management of Kawasaki disease was performed in most of the reported patients. Some children with MIS-C also present with shock; therefore, supportive care is critical in these cases.36,37 Both the American Academy of Pediatrics30 and the American College of Rheumatology guideline38 suggest that intravenous immunoglobulin (IVIG) at a dose of 2 g/kg, which prevents cardiac dysfunction in Kawasaki disease, would be beneficial in these patients. The fluid status and cardiac functions should be

**Table 4** Paraclinical evaluation in children with multisystem inflammatory syndrome in children

| Laboratory evaluation | CBC with differential |
|-----------------------|-----------------------|
|                       | BUN and creatinine, sodium, potassium, calcium, phosphorus, magnesium |
| Coagulation panel:     | PT, PT, D-dimer, fibrinogen |
| Creatinine kinase,     | LDH, C3, C4 |
| AST, ALT, bilirubin,   | albumin, Amylase |
| pro-BNP and troponin  | ESR, CRP, procalcitonin, ferritin, TG |
| BC                     | UA |
| Nasopharyngeal swab    | for SARS-CoV-2 by RT-PCR |

| Echocardiogram         |
|-----------------------|
| Imaging (if concerning symptoms/physical findings) |

Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; BC, blood culture; BUN, blood urea nitrogen; C3, complement component 3; CBC, complete blood count; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; LDH, lactate dehydrogenase; pro-BNP, pro-B-type natriuretic peptide; PT, prothrombin time; PTT, partial thromboplastin time; RT-PCR, reverse transcriptase polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TG, triglycerides; UA, urinalysis.
evaluated before IVIG administration. If they are not normal, the IVIG infusion rate should be reduced or the administration should be delayed. The immunomodulatory agents (e.g., corticosteroids and tocilizumab) that showed beneficial outcomes in similar diseases were also administered for children with this syndrome. However, there is no evidence that which drug or what dose is optimal, which necessitates the establishment of randomized clinical trials to investigate the effectiveness of these therapies.

### Cardiac Monitoring

One of the life-threatening organ involvements in MIS-C is cardiac involvement. Many cases present with a high troponin level (~80%) or brain natriuretic peptide (~84%), which indicates myocardial injury and consequently arrhythmia and cardiac dysfunction. Both the American Academy of Pediatrics and the Children's Hospital of Philadelphia Guideline advise that children with an abnormal ECG, echocardiogram, or high troponin should be referred to a pediatric cardiologist.

Coronary artery dilation and aneurysm have been reported in children with severe MIS-C, but they have also been seen in children with only fever and mild inflammation. Cardiac evaluation and follow-up are therefore necessary for all patients. It is essential to perform echocardiography for all cases and daily electrocardiogram (ECG) monitoring for patients with severe clinical presentation.

### Table 5: Suggested doses and other data for agents in the treatment of multisystem inflammatory syndrome in children

| Drug        | Indication                                         | Mechanism                  | Dosage                                      | Administration                     | Adverse effects                          |
|-------------|----------------------------------------------------|----------------------------|---------------------------------------------|-------------------------------------|------------------------------------------|
| Remdesivir  | \( \text{SpO}_2 < 94\% \) in a child with a positive PCR test and evidence of active infection | Viral RNA polymerase inhibition | Not on invasively- mechanical ventilation: (1) Patients more than 40 kg: 200 mg on day 1 followed by 100 mg on days 2–5 (2) Patients less than 40 kg: 5 mg/kg on day 1 followed by 2.5 mg/kg on days 2 to 5 Patients without any improvement after 5 d of treatment and patients on mechanical ventilation or ECMO: duration of therapy should be extended to 10 d | IV infusion over 30–120 min | Acute kidney injury (not recommended for patients with GFR less than 30 mL/min/1.73 m²) Transaminase elevation (not recommended for patients with amino-transferase 5 times the upper limit of normal) GI symptoms (e.g., nausea, vomiting) |
| IVIG        | Kawasaki disease features Shock Cardiac involvement Admission to PICU | Blocking the immune complex activation | 2 g/kg (max. 60 g) | IV infusion over 12 h (over 24–36 h in patients with shock) | Thrombosis Heart failure |
| Aspirin     | Patients with Kawasaki like features               | Anti-platelet               | 30–50 mg/kg                               | Oral                               | Not recommended for patients who are receiving Enoxaparin |
| Enoxaparin  | All patients                                       | Anti-thrombin               | 1 mg/kg B.I.D. (2 mg/kg in patients with symptoms of thrombosis) | IV (over 24–36 h in patients with shock) | Bleeding (not recommended for patients with PLT <50,000 or fibrinogen >100 or active bleeding) |
| Methylprednisolone | Severe or refractory shock Kawasaki disease like feature in addition to IVIG resistance Persistent fever despite IVIG administration | Immunosuppressant | 1–3 mg/kg/day B.I.D. 20–30 mg/kg for patients who presented with shock or are unresponsive to IVIG administration (max. 1 g/dose). It can be repeated three times in cases with shock and five times in patients with encephalopathy. | IV (Important note: only methylprednisolone succinate should be used in IV administration) | Exacerbation of lymphopeniaHTN |
| Tocilizumab | Refractory KD                                       | IL-6 inhibitor              | Infants: 8 mg/kg/dose (max. 800 mg/dose) Children: <30 kg: 12 mg/kg/dose >30 kg: 8 mg/kg/dose Note: In all patients, an additional dose can be repeated 12–24 h after the first administration | IV (over 60 min) | Increased lipid profile Volume retention HTN Hypersensitivity |

Abbreviations: ECMO, extracorporeal membrane oxygenation; GFR, glomerular filtration rate; HTN, hypertension; IVIG, intravenous immunoglobulin; KD, Kawasaki disease; PCR, polymerase chain reaction; PICU, pediatric intensive care unit; PLT, platelets.
The American College of Rheumatology guideline for MIS-C recommends repeating echocardiography at least 1 to 2 weeks and also 4 to 6 weeks after the onset of the syndrome.\textsuperscript{38} It should also be repeated 1 year after the onset of MIS-C for the children who had cardiac involvement detected during the previous echocardiograms. Patients with left ventricular (LV) dysfunction should have more echocardiograms. This guideline also recommends performing an MRI at 2 to 6 months after the diagnosis of MIS-C in patients with moderate-to-severe cardiac dysfunction to check for any scarring or fibrosis. An ECG should also be done in each follow-up session. In case of any conduction abnormalities, Holter monitoring is essential.

### Coagulopathy Prevention

As coagulopathy is an important issue in dealing with COVID-19-infected cases, anticoagulant therapy, including heparin or low molecular weight heparin (LMWH), is recommended in these patients.\textsuperscript{8,27} On the other hand, many children with MIS-C have a high D-dimer level. The American College of Rheumatology and the American Academy of Pediatrics suggest that aspirin at a dose of 3 to 5 mg/kg/day (up to 81 mg per day) is favorable in MIS-C cases with Kawasaki disease features, coronary artery aneurysm, or thrombocytosis.\textsuperscript{30,38} In children with coronary artery z-score > 10.0, enoxaparin or warfarin will be more beneficial. However, the Italian Society of Pediatric Infectious Diseases does not recommend prophylaxis with enoxaparin in children, except for patients who are at higher risk for thrombotic complications.\textsuperscript{28} The suggested dose for enoxaparin by this guideline is 150 to 300 unit/kg/day in neonates and 100 to 200 unit/kg/day for older pediatric patients.\textsuperscript{26}

The Tehran Children’s Medical Center Protocol\textsuperscript{31} suggests using aspirin at a dose of 30–50 mg/kg/day (the classic Kawasaki treatment) in patients who fulfill clinical criteria for complete Kawasaki disease with confirmed laboratory results. If the patient responds to the medication, the treatment is suggested to continue at a dose of 3 to 5 mg/kg/day plus echocardiography after 2 weeks and 2 months after diagnosis. The follow-up should be continued via echocardiography to rule out coronary artery aneurysms. The choice of agent, dosage, and duration should be consulted with a pediatric hematologist.\textsuperscript{42}

### Antivirals

Remdesivir is an intravenous nucleotide prodrug that prevents RNA polymerization of the virus and consequently reduces the replication of viral RNA. It has been shown that remdesivir reduces the duration of SARS-CoV-2 infection in adults. However, most children with MIS-C are not in the acute phase of the disease; therefore, the role of this agent in the management of MIS-C is limited. The guidelines by both the Italian Society of Pediatric Infectious Diseases\textsuperscript{28} and the American Pediatric Infectious Diseases Society\textsuperscript{38} suggest remdesivir as a preferred antiviral for COVID-19 treatment. In children who were tested positive for PCR and present with severe symptoms, the use of remdesivir could be effective.\textsuperscript{44} The protocol of remdesivir administration is summarized in Table 5, and we also recommend the same protocol.\textsuperscript{45}

Lopinavir and ritonavir are other antivirals that are recommended for severe cases by the Italian Society of Pediatric Infectious Diseases.\textsuperscript{28} These agents are the protease inhibitors that had been used in China for the treatment of pneumonia following the COVID-19 infection.\textsuperscript{46} These drugs are, however, contraindicated in premature neonates and neonates younger than 14 days. The recommended dose for children older than 12 months is 16.4 mg/kg twice a day.

### Corticosteroids

Steroids decrease the occurrence risk of coronary artery disorder in children with Kawasaki disease who are resistant to IVIG.\textsuperscript{47,48} The American College of Rheumatology reported that steroids at a dose of 1 to 2 mg/kg/day are sufficient in many children with MIS-C. It should be noted that some cases with shock required a high dose of intravenous (IV) glucocorticoids.\textsuperscript{38} Furthermore, this guideline and also the American Academy of Pediatrics recommend tapering the dose of steroids over 2 to 3 weeks, regardless of the dosage, to prevent rebound inflammation.\textsuperscript{30}

The RECOVERY trial (a large randomized clinical trial) indicated that low-to-moderate doses of dexamethasone are beneficial in patients with severe illness who are on mechanical ventilation. New findings showed that a low dose of dexamethasone may suppress the immune response and reduce the subsequent inflammatory diseases.\textsuperscript{44,49,50}

The Italian Society of Pediatric Infectious Diseases recommends methylprednisolone at a dose of 1 to 2 mg/kg/day (maximum 80 mg) for 2 to 5 days, in children with worsening pulmonary function and a high level of inflammatory indicators in the laboratory data.\textsuperscript{28} Moreover, in severe cases, the administration of high-dose dexamethasone (30 mg/kg) should be considered. This guideline also recommends considering dexamethasone at a dose of 0.2 to 0.4 mg/kg (maximum 6 mg) in patients who require supplemental oxygen therapy.

### Biologic Drugs

The American College of Rheumatology guideline\textsuperscript{38} recommends using immunomodulatory agents in severe COVID-19 infected cases, patients with shock or acute respiratory distress syndrome (ARDS), or children with signs of hyperinflammation in the laboratory data, including a high level of LDH (normal range: 140–280 units per liter), ferritin (newborns: 25–200 ng/mL, less than 1 month: 200–600 ng, 2 to 5 months: 50–200 ng, 6 months to 15 years: 7–142 ng), D-dimer (normal range: less than 250 ng/mL), IL-1 (normal range: 0–5 pg/mL), IL-6 (normal range: lower than 6.6 pg/mL), and CRP (normal range: lower than 5 mg/L).

---

Table 6. Supplements that our center recommends for children with multisystem inflammatory syndrome in children

| Supplement                  | Dosage                        |
|-----------------------------|-------------------------------|
| Vitamin C (not recommended for patients with diabetes mellitus or G6PD deficiency) | 50–200 mg/kg (IV) |
| Zinc                        | 5 times of daily requirement  |
| Thiamin                     | 100–300 mg/day                |
| Vitamin D                   | 2,000–3,000 unit/day          |

---

Correlation table of inflammatory indicators in children with MIS-C><br>Correlation table of inflammatory indicators in children with MIS-C

| Inflammatory Indicator | Normal Range |
|------------------------|--------------|
| IL-6                   | <6.6 pg/mL   |
| CRP                    | <250 ng/mL   |
| Ferritin (newborns)    | 25–200 ng/mL |
| D-dimer                | <7–142 ng    |
range: 0–10 mg/L). However, some contraindications declared by the Italian Society of Pediatric Infectious Diseases are (1) transaminases > 5 times the normal level, (2) being allergic to these drugs, (3) severe neutropenia, (4) bowel perforation or diverticulitis, and (5) platelets <50,000 count.

The American College of Rheumatology guideline suggests that anakinra (an IL-1 receptor inhibitor) at a dose of 10 mg/kg/day might be beneficial in Kawasaki disease patients with a severe condition who are irresponsive to IVIG. An ongoing clinical trial (KAWAKINRA, ClinicalTrials.gov: NCT02390596) showed favorable results when using anakinra in patients with severe manifestations. The preferred dosage of anakinra for patients with cytokine storm syndromes by the panelists of the Italian Society of Pediatric Infectious Disease is 8 to 10 mg/kg/day in two or four divided IV doses for 2 to 3 days. The D-dimer and plasma level of IL-6 should be evaluated after 48 to 72 hours.

Tocilizumab is an IL-6 receptor inhibitor that is used for juvenile idiopathic arthritis. This illness mimics Kawasaki disease in some manifestations, such as rash, arthritis, fever, and high ferritin level. This agent has shown promising results in the management of COVID-19 in adults, and an ongoing clinical trial (CORIMUNO-19, ClinicalTrials.gov: NCT04331808) tested this drug, and the results were encouraging. The suggested dosage by the Italian Society of Pediatric Infectious Diseases guideline is 10 to 12 mg/kg for patients <30 kg and 8 mg/kg for >30 kg (maximum 800 mg).

When to Discharge?

Patients who have been afebrile for at least 24 hours can be discharged from the hospital once they are well hydrated and do not require supplemental oxygen. Furthermore, their laboratory data and vital signs should show an improving trend.

Conclusion

The available reports about MIS-C indicated that these patients can deteriorate quickly, and the management of this syndrome requires different pediatric specialists. Therefore, children with moderate to severe conditions should be hospitalized in a well-equipped center with PICU. The choice of treatment and protocol is based on the severity of clinical presentation and the experts' opinions.

Funding

None.

Conflict of Interest

None declared.

References

1. Ghodsì A, Azafar A, Ghahremani S. A review of coronavirus disease (COVID-19) in children. J Pediatr Neurol 2020;8(03):
2. Farhat AS, Sayedi SJ, Akhlaghi F, Hamedi A, Ghodsì A. Coronavirus (COVID-19) infection in newborns. Int J Pediatr 2020;8(06):11513–11517
3. Zhu N, Zhang D, Wang W, et al; China Novel Coronavirus Investigation and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382(08):727–733
4. Gorbalenya AE, Baker SC, Baric R, et al. Severe acute respiratory syndrome-related coronavirus: the species and its viruses—a statement of the Coronavirus Study Group. BioRxiv 2020
5. Hedrich CM, Schnabel A, Hospach T. Kawasaki disease. Front Pediatr 2018;6:198
6. Turnier JL, Anderson MS, Heizer HR, Jone P-N, Glodé MP, Dominguez SR. Concurrent respiratory viruses and Kawasaki disease. Pediatr Infections 2015;136(03):e609–e614
7. Catalano-Pons C, Quartier P, Leruez-Ville M, et al. Primary cytomegalovirus infection, atypical Kawasaki disease, and coronary aneurysms in 2 infants. Clin Infect Dis 2005;41(05):e53–e56
8. Whittaker E, Bamford A, Kenny J, et al; PIMS-TS Study Group and EUCLIDS and PERFORM Consortia. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA 2020;324(03):259–269
9. Nakra NA, Blumberg DA, Herrera-Guerra A, Lakshminrusimha S. Multi-sysym inflammatory syndrome in children (MIS-C) following SARS-CoV-2 infection: review of clinical presentation, hypothetical pathogenesis, and proposed management. Children (Basel) 2020;7(07):69
10. Guidance - Paediatric multisystem inflammatory syndrome temporally associated with COVID-19: The Royal College of Paediatrics and Child Health. Accessed 2020 at: https://www.rcpch.ac.uk/resources/guidance-paediatric-multisystem-inflammatory-syndrome-temporally-associated-covid-19-pims
11. World Health Organization Scientific Brief. Multisystem inflammatory syndrome in children and adolescents with COVID-19. Accessed 2020 at: https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children- adolescents-with-covid-19
12. Health Alert Network (HAN) Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19). Accessed 2019 at: https://emergency.cdc.gov/han/han00432.asp
13. McCreindell BW, Rowley AH, Newburger JW, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Epidemiology and Prevention. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement from the American Heart Association. Circulation 2017;135(17):e927–e999
14. Newburger JW, Takahashi M, Gerber MA, et al; Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease Council on Cardiovascular Disease in the Young American Heart Association American Academy of Pediatrics. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the American Heart Association. Circulation 2020;142(03):e999–e1020
15. Verdini L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet 2020;395(10239):1771–1778
16. Toubiana J, Poirault C, Corsia A, et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. BMJ 2020;369:m2094
17. Cheung EW, Zachariah P, Gorelik M, et al. Multisystem inflammatory syndrome related to COVID-19 in previously healthy children and adolescents in New York City. JAMA 2020;324(03):294–296
18. Belhadjer Z, Mété M, Bajolle F, et al. Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic. Circulation 2020
Treatment Guidelines of SARS-CoV-2 Related MIS-C

19 Kanegaye JT, Wilder MS, Molkara D, et al. Recognition of a Kawasaki disease shock syndrome. Pediatrics 2009;123(05):e783–e789
20 Esper F, Weibel C, Ferguson D, Landry ML, Kahn JS. Evidence of a novel human coronavirus that is associated with respiratory tract disease in infants and young children. J Infect Dis 2005;191(04):492–498
21 Esper F, Shapiro ED, Weibel C, Ferguson D, Landry ML, Kahn JS. Association between a novel human coronavirus and Kawasaki disease. J Infect Dis 2005;191(04):499–502
22 Ghodsi A, Malek A, Gahremani S. A review of multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19. Hormozgan Medical J 2020;24(04):
23 Feldstein LR, Rose EB, Horwitz SM, et al; Overcoming COVID-19 Investigators CDC COVID-19 Response Team. Multisystem inflammatory syndrome in US children and adolescents. N Engl J Med 2020;383(04):334–346
24 Zou H, Lu J, Liu J, et al. Characteristics of pediatric multi-system inflammatory syndrome (PMIS) associated with COVID-19: a meta-analysis and insights into pathogenesis. Int J Infect Dis 2021;102:319–326
25 Shulman S. Pediatric COVID-associated multi-system inflammatory syndrome (PMIS). J Pediatr Inf Disc Soc 2020. DOI: 10.1093/jpids/piaa061
26 Ghodsi A, Mahmoudabadie E, Gahremani S, Malek A. Cardiac manifestations of multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2 infection. Arch Pediatr Infect Dis 2021. DOI: 10.5812/ pedinfect.109915
27 Girmaud M, Starck J, Levy M, et al. Acute myocardiitis and multisystem inflammatory emerging disease following SARS-CoV-2 infection in critically ill children. Ann Intensive Care 2020;10(01):69
28 Venturini E, Montagnani C, Garazzino S, et al; Italian SITIP-SIP SARS-CoV-2 pediatric infection study group. Treatment of children with COVID-19: position paper of the Italian Society of Pediatric Infectious Disease. Ital J Pediat 2020;46(01):139
29 Information for healthcare providers about multisystem inflammatory syndrome in children (MIS-C). Accessed 2020 at: https://www.cdc.gov/mis-c/hcp/
30 American academy of pediatrics. Accessed 2019 at:https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/multisystem-inflammatory-syndrome-in-children-mis-c-interim-guidance/
31 Ziaee V, Assari R, Mamishi S, et al. An algorithmic approach to multisystem inflammatory syndrome in children with COVID-19: Tehran Children’s Medical Center Protocol. Iran J Pediatr 2020;30(05):
32 children’s hospital of philadelphia guideline. Accessed 2020 at: https://www.chop.edu/clinical-pathway/multisystem-inflammatory-syndrome-mis-c-clinical-pathway
33 Alhazzani W, Muller MH, Arabi YM, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med 2020;46(05):854–887
34 Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocaris P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 2020;395(10237):1607–1608
35 Chiotos K, Bassiri H, Behrens EM, et al. Multisystem inflammatory syndrome in children during the COVID-19 pandemic: a case series. J Pediatric Infect Dis Soc 2020
36 Deza Leon MP, Redzepi A, McGrath E, et al. COVID-19–associated pediatric multisystem inflammatory syndrome. J Pediatric Infect Dis Soc 2020;9(03):407–408
37 Hennon TR, Penque MD, Abdul-Aziz R, et al. COVID-19 associated multisystem inflammatory syndrome in children (MIS-C) guidelines; a Western New York approach. Prog Pediatr Cardiol 2020: 101232
38 Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology Clinical Guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 1. Arthritis Rheumatol 2020;72(11):1791–1805
39 Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology Clinical Guidance for pediatric patients with multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2 and hyperinflammation in COVID-19. version 2. Arthritis Rheumatol 2020. DOI: 10.1002/art.41616
40 Capone CA, Subramony A, Sweber T, et al; Northwell Health COVID-19 Research Consortium. Characteristics, cardiac involvement, and outcomes of multisystem inflammatory syndrome of childhood associated with severe acute respiratory syndrome coronavirus 2 infection. J Pediatr 2020;224:141–145
41 Ouldali N, Toubiana J, Antona D, et al; French Covid-19 Paediatric Inflammation Consortium. Association of intravenous immunoglobulins plus methylprednisolone vs immunoglobulins alone with course of fever in multisystem inflammatory syndrome in children. Jama 2021;325(09):855–864
42 Jiang L, Tang K, Levin M, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis 2020;20(11):e276–e288
43 Chiotos K, Hayes M, Kimberlin DW, et al. Multicenter initial guidance on use of antivirals for children with COVID-19/SARS-CoV-2. J Pediatric Infect Dis Soc 2020
44 Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19—preliminary report. N Engl J Med 2020
45 Loke Y-H, Berul CI, Harahsheh AS. Multisystem inflammatory syndrome in children associated with Kawasaki disease: is there a linkage to Kawasaki disease? Trends Cardiovasc Med 2020;30(07):389–396
46 Zhao J-Y, Yan J-Y, Qu J-M. Interpretations of “diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7)”. Chin Med J (Engl) 2020;133(11):1347–1349
47 Kobayashi T, Saji T, Otani T, et al; RAISE study group investigators. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 2012;379(9826):1613–1620
48 Wardle AJ, Connolly GM, Seager MJ, Tulloh RM. Corticosteroids for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 2017;1(01):CD011188
49 Horby P, Landrain M. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. Nuffield Dept Population Health Accessed 2020 at: https://www.remapcap.org/covid19publications/low-cost-dexamethasone-reduces-death-by-up-to-one-third-in-hospitalised-patients-with-severe-respiratory-complications-of-covid-19
50 Horby P, Matham M, Linsell L, et al. Effect of hydroxychloroquine in hospitalized patients with COVID-19: preliminary results from a multi-centre, randomised, controlled trial. MedRxiv2020
51 Hadjadji J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and exacerbated inflammatory responses in severe COVID-19 patients. MedRxiv2020
52 Trouillet-Assant S, Viel S, Gaymard A, et al; COVID HCL Study group. Type I IFN immunoprofiling in COVID-19 patients. J Allergy Clin Immunol 2020;146(01):206–208.e2